Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
Journal: The New England journal of medicine
Published: October 22, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: October 08, 2024
"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotype.
Journal: The oncologist
Published: July 06, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: December 18, 2023
MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen species.
Journal: bioRxiv : the preprint server for biology
Published: November 28, 2023
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 30, 2023
Diseases of Hereditary Renal Cell Cancers.
Journal: The Urologic clinics of North America
Published: March 22, 2023
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL.
Journal: Journal of kidney cancer and VHL
Published: June 28, 2022
Last Updated: 09/26/2026